What the heck is going on here? More than likely, this move has to do with the anticipation of GW Pharmaceuticals’ filing for a new drug application (NDA) with the Food and Drug Administration (FDA) for Epidiolex very soon. Epidiolex is an oral cannabinoid-based medicine that, in phase 3 clinical trials, generated a statistically significant reduction in seizure frequency for patients with two rare types of childhood-onset epilepsy, Dravet syndrome and Lennox-Gastaut syndrome. GW Pharmaceuticals’ management team has suggested that investors expect an NDA filing by mid-2017, which would signal it’s due any time now. If Epidiolex gets a green light from the FDA, and it’s fortunate enough to expand its label beyond just the two aforementioned rarer types of epilepsy, it could make a run at perhaps $1 billion in peak annual sales. This is why investors are so bullish regarding GW Pharmaceuticals. Still, we’ll need to see if the FDA grants the company a priority review, which would shorten the NDA review period by four months to a six-month process and get Epidiolex to market quickly. Further, an approval is no guarantee for a cannabinoid-based product. Likewise, with the company’s only Marijuana Stocks other approved product (outside the U.S.), Sativex, failing to garner much in the way of sales, there are concerns about GW Pharmaceuticals’ effectiveness in marketing and pricing Epidiolex, if approved. For the time being, the company’s stock appears priced for perfection. Unlike GW Pharmaceuticals, where hope seems to reign supreme, three press releases over the past couple of weeks have been wholly responsible for Aurora Cannabis’ ( NASDAQOTH:ACBFF ) charge higher. In just two weeks, the Canadian medical-cannabis producer and retailer has seen its share price rocket 29% higher.